Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Nektar Therapeutics shares valued at $7,863 were sold by Zalevsky Jonathan on Nov 19 ’24. At $1.01 per share, Zalevsky Jonathan sold 7,785 shares. The insider’s holdings dropped to 243,019 shares worth approximately $0.25 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Wilson Mark Andrew sold 6,407 shares, netting a total of over 6,471 in proceeds. Following the sale of shares at $1.01 each, the insider now holds 218,856 shares.
Before that, ROBIN HOWARD W had sold 16,278 shares from its account. In a trade valued at $16,441, the President & CEO traded Nektar Therapeutics shares for $1.01 each. Upon closing the transaction, the insider’s holdings decreased to 16,278 shares, worth approximately $0.85 million.
As published in their initiating research note from H.C. Wainwright on December 10, 2024, Nektar Therapeutics [NKTR] has been a Buy and the price target has been revised to $6.50. Analysts at Piper Sandler started covering the stock with ‘”an Overweight”‘ outlook in a report released in early November. Earlier on June 28, 2024, Rodman & Renshaw initiated its rating. Their recommendation was “a Buy” for NKTR stock.
Analyzing NKTR Stock Performance
Over the course of the year, Nektar Therapeutics shares have jumped approximately 80.53%. Shares of the company reached a 52-week high of $1.9280 on 05/13/24 and a 52-week low of $0.4800 on 01/18/24. A 50-day SMA is recorded $1.2308, while a 200-day SMA reached $1.2588. Nevertheless, trading volume fell to 1.74 million shares from 1.85 million shares the previous day.
Support And Resistance Levels for Nektar Therapeutics (NKTR)
According to the 24-hour chart, there is a support level at 0.9931, which, if violated, would cause prices to drop to 0.9663. In the upper region, resistance lies at 1.0484. The next price resistance is at 1.0769. RSI (Relative Strength Index) is 38.20 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.0440, which suggests the price will decrease in the coming days. Percent R is at 79.43%, indicating bearish price movement. Stochastics %K at buying indicates that the stock is to be held.
